D.E. Shaw & Co
ACAD icon

D.E. Shaw & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

D.E. Shaw & Co’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-47,000
Closed -$1.42M – 3447
2017
Q4 		$1.42M Hold
47,000
– – ﹤0.01% 2376
2017
Q3 		$1.77M Hold
47,000
– – ﹤0.01% 2119
2017
Q2 		$1.31M Sell
47,000
-34,100
-42% -$1.02M ﹤0.01% 2243
2017
Q1 		$2.79M Sell
81,100
-20,000
-20% -$706K ﹤0.01% 1641
2016
Q4 		$2.92M Buy
101,100
+31,100
+44% +$823K 0.01% 1728
2016
Q3 		$2.23M Buy
70,000
+40,000
+133% +$1.36M ﹤0.01% 1846
2016
Q2 		$974K Buy
30,000
+10,000
+50% +$335K ﹤0.01% 2424
2016
Q1 		$559K Buy
+20,000
New +$436K ﹤0.01% 2722
2015
Q1 		– Sell
-134,100
Closed -$4.26M – 3586
2014
Q4 		$4.26M Hold
134,100
– – 0.01% 1689
2014
Q3 		$3.32M Hold
134,100
– – ﹤0.01% 1836
2014
Q2 		$3.03M Sell
134,100
-2,300
-2% -$48K ﹤0.01% 1983
2014
Q1 		$3.32M Sell
136,400
-42,600
-24% -$1.08M ﹤0.01% 1902
2013
Q4 		$4.47M Sell
179,000
-3,600
-2% -$84.9K 0.01% 1778
2013
Q3 		$5.02M Buy
182,600
+22,600
+14% +$472K 0.01% 1590
2013
Q2 		$2.9M Buy
+160,000
New +$2.2M 0.01% 1781

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

D.E. Shaw & Co's ACAD Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Acadia Pharmaceuticals (ACAD) stake by 29% in Q1 2026, selling an estimated $7.1M and leaving 729,836 shares worth $16.2M. The position accounts for 0.01% of the portfolio, ranked #1281.

D.E. Shaw & Co first reported a position in ACAD in Q2 2013 and has held it in 48 quarters since. The position peaked at $126M in Q2 2023. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • D.E. Shaw & Co held 729,836 shares of Acadia Pharmaceuticals worth $16.2M as of Q1 2026.
  • D.E. Shaw & Co sold 296,949 Acadia Pharmaceuticals shares in Q1 2026, an estimated $7.1M.
  • Acadia Pharmaceuticals made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1281 holding.
  • D.E. Shaw & Co first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
  • D.E. Shaw & Co's Acadia Pharmaceuticals position peaked at $126M in Q2 2023.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.